EUFEST STUDY PDF

The European First Episode Schizophrenia Trial (EUFEST): Comparison of outcome in The European study of the effectiveness of haloperidol, amisulpride . The study helps solve the question of which category of antipsychotic medications best address impaired cognition, which affects a significant. The EUFEST study then undertook with a pragmatic open randomized-controlled trial design to compare the effectiveness of second-generation antipsychotic.

Author: Mezijar Kiktilar
Country: Nicaragua
Language: English (Spanish)
Genre: Sex
Published (Last): 13 January 2012
Pages: 473
PDF File Size: 18.88 Mb
ePub File Size: 13.9 Mb
ISBN: 861-3-55096-613-9
Downloads: 26793
Price: Free* [*Free Regsitration Required]
Uploader: Tarisar

The presence of one or more of the contraindications against any of the study drugs.

Psychopathology – positive symptoms, negative symptoms, depression, agitation-excitement, disorganisation 2. Home Who are we? SchizophreniaSchizophreniform disorderSchizoaffective disorder. Diagnosis of schizophrenia; 2.

The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial.

The principal investigators are Prof. Comparisons with haloperidol showed lower risks for any-cause discontinuation with amisulpride hazard ratio [HR] 0. Secondary measures include changes in different dimensions of psychopathology, side effects, compliance, social needs, quality of life, substance abuse and cognitive functions. Side effects – extrapyramidal symptoms EPS side-effect profile, sexual side effects and weight gain 3. Multicentre, randomised active controlled, parallel group trial.

The study should be finished by the end of and it is expected ejfest results will yield relevant clinical information with regard to the effectiveness of the second generation antipsychotics. Analysis was by intention to treat. The primary outcome measure is retention in treatment, defined as time to discontinuation of study drug. These and other facts have stimulated discussions regarding the effectiveness of the new sutdy of antipsychotics.

The presence of one or more of the contra-indications against any of the study drugs. Natural history of schizophrenia. Schizophreniform or schizoaffective disorder; 3. Quality of life 6. Ethics approval received from the local medical ethics committee. We aimed to compare the effectiveness of second-generation antipsychotic drugs with that of a low dose of haloperidol, in first-episode schizophrenia.

However, we cannot conclude that second-generation drugs are more efficacious than is haloperidol, since discontinuation rates are not necessarily consistent with symptomatic improvement. Intolerance to one of the drugs in this study; 4. Result of results found for within.

The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial.

Most studies comparing second generation antipsychotics with classical neuroleptics have been conducted in more or less chronic schizophrenia patients. What is the effectiveness of low doses of haloperidol and regular doses of amisulpride, olanzapine, quetiapine, and ziprasidone on loss of one year retention in patients with recent onset of schizophrenia, schizoaffective, and schizophreniform disorder?

Second-generation antipsychotic drugs were introduced over a decade ago for the treatment of schizophrenia; however, their purported clinical effectiveness compared with first-generation antipsychotic drugs is still debated.

This outcome is assessed at regular time intervals until 12 months after recruitment. Eligibility Participant ekfest criteria 1. Eligible patients were aged years, and met diagnostic criteria for schizophrenia, schizophreniform disorder, or schizoaffective disorder. Rationale and design of the trial. Comparison of outcome in first episode schizophrenia with different low dose antipsychotic drug regimens.

This effort represents the first independently designed trans-European schizophrenia treatment trial. The Lancet ; The aim of the European First Episode Schizophrenia Trial Eifest is to compare treatment with amisulpride, quetiapine, olanzapine and ziprasidone to a low dose of haloperidol in an unselected sample of first episode schizophrenia patients with minimal prior exposure to tsudy.

We did an open randomised controlled trial of haloperidol versus second-generation antipsychotic drugs in 50 sites, in 14 countries.

Previous Trial Back to results Next Trial. Genetic determinants of response to antipsychotic drugs 9.

Study information Scientific title The European study of the effectiveness of haloperidol, amisulpride, olanzapine, quetiapine, and ziprasidone on loss of retention in first eufset schizophrenia Acronym EUFEST Study hypothesis What is the effectiveness of low doses of haloperidol and regular doses of amisulpride, olanzapine, quetiapine, and ziprasidone euffst loss of one year retention in patients with recent onset of schizophrenia, schizoaffective, and schizophreniform disorder?

Such studies were usually conducted in highly selected samples, and were generally designed and financed by the manufacturer of the drug tested. Intolerance to one of the drugs in this study 4. Retention to allocated study drug, which is the time that the patient stays on the randomised drug within the study dose range.

Patients and their treating physicians were not blinded to the assigned treatment. PfizerAstraZenecaSanofi-Aventis. At present, more than patients have been recruited and randomized in the following countries: The European study of the effectiveness of haloperidol, amisulpride, olanzapine, quetiapine, and ziprasidone on loss of retention in first episode schizophrenia.

What is the effectiveness of low doses of haloperidol and regular doses of amisulpride, olanzapine, quetiapine, and ziprasidone on loss of one year retention in patients with recent onset of schizophrenia, schizoaffective, and schizophreniform disorder? Amisulpride, Haloperidol, Olanzapine, Quetiapine, Ziprasidone.

Evid Based Ment Health.

The European study of the effectiveness of haloperidol, amisulpride, olanzapine, quetiapine, and ziprasidone on loss of retention in first episode schizophrenia. The primary outcome measure was all-cause treatment discontinuation. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: